Phase 1/2a Study of ICT01 Plus Low Dose SC IL-2 in Patients With Advanced Solid Tumors
Clinical trial NCT05307874 · TERMINATED
Trial details
- NCT number
- NCT05307874
- Sponsor
- ImCheck Therapeutics, an Ipsen company
- Status
- TERMINATED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-05-04
- Primary completion
- 2025-10-09
- Enrollment
- 56
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.